Takeda Pharmaceutical Company Ltd

🇸🇪Sweden

Country: 🇸🇪Sweden

Ownership: -

Established: 1925-01-01

Employees: -

Market Cap: $47.5B

Website: http://www.takeda.co.jp/

Clinical Trials

Efficacy of Tinoridine in Treating Pain and Inflammation in Adults

Phase 4

Completed

Conditions: Pain
Inflammation

Interventions: Drug: Tinoridine HCl
Drug: Placebo

First Posted Date: 2010-10-20

Last Posted Date: 2012-01-12

Lead Sponsor: Takeda

Target Recruit Count: 342

Registration Number: NCT01224756

Effect of Dexlansoprazole on Bone Homeostasis

Phase 1

Completed

Conditions: Homeostasis
Bone and Bones

Interventions: Drug: Placebo
Drug: Dexlansoprazole
Drug: Esomeprazole

First Posted Date: 2010-10-07

Last Posted Date: 2024-03-18

Lead Sponsor: Takeda

Target Recruit Count: 115

Registration Number: NCT01216293

TachoSil® Versus Surgicel® Original for the Secondary Treatment of Local Bleeding in Adult and Pediatric Patients Undergoing Hepatic Resection Surgery

Phase 3

Completed

Conditions: Hemorrhage

Interventions: Device: Surgicel® Original
Biological: TachoSil®

First Posted Date: 2010-08-31

Last Posted Date: 2015-11-25

Lead Sponsor: Takeda

Target Recruit Count: 253

Registration Number: NCT01192022

Safety and Efficacy Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder

Phase 3

Completed

Conditions: Depressive Disorder, Major

Interventions: Drug: Placebo
Drug: Vortioxetine

First Posted Date: 2010-08-11

Last Posted Date: 2013-12-18

Lead Sponsor: Takeda

Target Recruit Count: 469

Registration Number: NCT01179516

Bivalent Norovirus Vaccine Study

Phase 1

Completed

Conditions: Gastroenteritis

Interventions: Biological: Saline
Biological: NoV GI.1/GII.4 Bivalent VLP Vaccine

First Posted Date: 2010-07-23

Last Posted Date: 2018-11-23

Lead Sponsor: Takeda

Target Recruit Count: 102

Registration Number: NCT01168401

Locations: 🇺🇸
Saint Louis University, Saint Louis, Missouri, United States
🇺🇸
Navy Medical Research Center, Silver Springs, Maryland, United States
🇺🇸
University of Rochester Medical Center, Rochester, New York, United States

Efficacy and Safety Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder

Phase 3

Completed

Conditions: Depressive Disorder, Major

Interventions: Drug: Placebo
Drug: Vortioxetine

First Posted Date: 2010-07-15

Last Posted Date: 2013-12-18

Lead Sponsor: Takeda

Target Recruit Count: 462

Registration Number: NCT01163266

Safety and Efficacy of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder

Phase 3

Completed

Conditions: Depressive Disorder, Major

Interventions: Drug: Placebo
Drug: Vortioxetine
Drug: Duloxetine

First Posted Date: 2010-06-29

Last Posted Date: 2013-12-18

Lead Sponsor: Takeda

Target Recruit Count: 614

Registration Number: NCT01153009

Safety and Tolerability of Vortioxetine (LuAA21004) - Open Label Extension Study

Phase 3

Completed

Conditions: Depressive Disorder, Major

Interventions: Drug: Vortioxetine

First Posted Date: 2010-06-29

Last Posted Date: 2014-05-28

Lead Sponsor: Takeda

Target Recruit Count: 1075

Registration Number: NCT01152996

Safety and Efficacy of Lansoprazole in Patients With Reflux Disease

Phase 4

Completed

Conditions: Gastroesophageal Reflux

Interventions: Drug: Lansoprazole

First Posted Date: 2010-06-02

Last Posted Date: 2012-09-03

Lead Sponsor: Takeda

Target Recruit Count: 506

Registration Number: NCT01135368

Pantoprazole Magnesium 40 mg Versus Esomeprazole 40 mg in Patients With Erosive Gastroesophageal Reflux Disease

Phase 3

Completed

Conditions: GERD

Interventions: Drug: Magnesium Pantoprazole
Drug: Magnesium Esomeprazole

First Posted Date: 2010-05-28

Last Posted Date: 2012-06-26

Lead Sponsor: Takeda

Target Recruit Count: 713

Registration Number: NCT01132638

Locations: 🇧🇷
Investigational site, São Paulo/SP, Brazil

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy